AKERO THERAPEUTICS IN

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

10 ноя 2023 05:57:33 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

08 ноя 2023 04:00:01 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

17 окт 2023 13:05:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

10 окт 2023 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

09 окт 2023 13:05:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology

04 окт 2023 05:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in September

31 авг 2023 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

28 авг 2023 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

11 авг 2023 03:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology

23 июн 2023 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease

05 июн 2023 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1

01 июн 2023 13:05:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Healthcare Conference

31 май 2023 05:00:01 Источник Nasdaq GlobeNewswire

Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock

16 май 2023 15:53:36 Источник Nasdaq GlobeNewswire

Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

15 май 2023 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH

29 мар 2023 13:01:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

17 мар 2023 04:00:00 Источник Nasdaq GlobeNewswire

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

10 янв 2023 05:00:01 Источник Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 янв 2023 05:00:01 Источник Nasdaq GlobeNewswire

Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones

21 дек 2022 13:01:00 Источник Nasdaq GlobeNewswire